LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1. - Dataset (ID:20240)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | GW843682X | 3.33 | uM | LJP6 | 72 | hr | 868 | 1029 | 3486 | 0.2953 | 0.0617 |
MDA-MB-231 | HG-5-113-01 | 3.33 | uM | LJP5 | 72 | hr | 868 | 1179 | 3486 | 0.3382 | 0.1187 |
MDA-MB-231 | HG-5-88-01 | 3.33 | uM | LJP6 | 72 | hr | 868 | 2204 | 3486 | 0.6324 | 0.5105 |
MDA-MB-231 | Imatinib | 3.33 | uM | LJP6 | 72 | hr | 868 | 3697 | 3486 | 1.0605 | 1.0806 |
MDA-MB-231 | JNK-9L | 3.33 | uM | LJP6 | 72 | hr | 868 | 850 | 3486 | 0.2440 | -0.0067 |
MDA-MB-231 | JW-7-24-1 | 3.33 | uM | LJP6 | 72 | hr | 868 | 1881 | 3486 | 0.5395 | 0.3869 |
MDA-MB-231 | Lapatinib | 3.33 | uM | LJP6 | 72 | hr | 868 | 3373 | 3486 | 0.9677 | 0.9569 |
MDA-MB-231 | LDN-193189 | 3.33 | uM | LJP5 | 72 | hr | 868 | 1081 | 3486 | 0.3102 | 0.0814 |
MDA-MB-231 | Linifanib | 3.33 | uM | LJP6 | 72 | hr | 868 | 3880 | 3486 | 1.1130 | 1.1505 |
MDA-MB-231 | Linsitinib | 3.33 | uM | LJP5 | 72 | hr | 868 | 2739 | 3486 | 0.7856 | 0.7146 |
MDA-MB-231 | Mitoxantrone | 3.33 | uM | LJP5 | 72 | hr | 868 | 668 | 3486 | 0.1917 | -0.0763 |
MDA-MB-231 | Mitoxantrone | 3.33 | uM | LJP6 | 72 | hr | 868 | 645 | 3486 | 0.1851 | -0.0851 |
MDA-MB-231 | MK2206 | 3.33 | uM | LJP6 | 72 | hr | 868 | 2585 | 3486 | 0.7416 | 0.6559 |
MDA-MB-231 | Neratinib | 3.33 | uM | LJP5 | 72 | hr | 868 | 1563 | 3486 | 0.4484 | 0.2655 |
MDA-MB-231 | Nilotinib | 3.33 | uM | LJP5 | 72 | hr | 868 | 2376 | 3486 | 0.6817 | 0.5762 |
MDA-MB-231 | Nintedanib | 3.33 | uM | LJP6 | 72 | hr | 868 | 2488 | 3486 | 0.7138 | 0.6189 |
MDA-MB-231 | NU7441 | 3.33 | uM | LJP5 | 72 | hr | 868 | 1978 | 3486 | 0.5675 | 0.4242 |
MDA-MB-231 | Dactolisib | 3.33 | uM | LJP5 | 72 | hr | 868 | 1479 | 3486 | 0.4242 | 0.2333 |
MDA-MB-231 | NVP-TAE684 | 3.33 | uM | LJP6 | 72 | hr | 868 | 1419 | 3486 | 0.4072 | 0.2107 |
MDA-MB-231 | Palbociclib | 3.33 | uM | LJP6 | 72 | hr | 868 | 1584 | 3486 | 0.4543 | 0.2734 |
MDA-MB-231 | PD0325901 | 3.33 | uM | LJP5 | 72 | hr | 868 | 941 | 3486 | 0.2699 | 0.0278 |
MDA-MB-231 | PD0325901 | 3.33 | uM | LJP6 | 72 | hr | 868 | 861 | 3486 | 0.2472 | -0.0025 |
MDA-MB-231 | PD173074 | 3.33 | uM | LJP6 | 72 | hr | 868 | 3652 | 3486 | 1.0475 | 1.0632 |
MDA-MB-231 | PD184352 | 3.33 | uM | LJP5 | 72 | hr | 868 | 1861 | 3486 | 0.5340 | 0.3795 |
MDA-MB-231 | Pelitinib | 3.33 | uM | LJP5 | 72 | hr | 868 | 1535 | 3486 | 0.4404 | 0.2548 |